DOTA Conjugated JM#21 derivative 7 

DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney^[1].

CXCR4^[1]

1471.75

C₆₆H₁₁₄N₂₂O₁₆

3033865-40-3

{d-Ile}-LRWSRK-Lys(DOTA)-NH2

{d-Ile}-Leu-Arg-Trp-Ser-Arg-Lys-Lys(DOTA)-NH2

O=C([C@H](N)[C@@H](CC)C)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CCCCNC(CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)=O)=O)CCCCN)=O)CCCNC(N)=N)=O)CO)=O)CC2=CNC3=CC=CC=C23)=O)CCCNC(N)=N)=O)CC(C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gaonkar RH, et al. Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications. J Med Chem. 2023 Jul 13;66(13):8484-8497.  [Content Brief]